EANS-Adhoc: Oxygen Biotherapeutics TBI Study To Be Offered to Injured Israel-based Soldiers

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

08.09.2010

DURHAM, NC, September 7, 2010 — Oxygen Biotherapeutics, Inc. (NASDAQ and SIX
Swiss Exchange: OXBT), a development stage biomedical company focused on
developing oxygen-rich intravenous and topical products, today announced that
Israeli soldiers who suffer severe traumatic brain injury (TBI) can be enrolled
in the company´s Phase II-b STOP-TBI trials at clinical sites in Israel. In
view of this development, the company announced that it seeks to amend the
existing study protocol to broaden the qualified patient enrollment population
to include moderate/mild TBI patients. The company expects to reconvene
enrollment in its second cohort after the required regulatory adjustments have
been approved. The result of these two actions should increase the patient
population that qualifies for enrollment in the study.

"Today, traumatic brain injury is one of the most common impairments faced by
military personnel all over the world. Land mines, rocket-propelled grenades and
improvised explosive devices are now the most common tools of war. When they
strike, body armor and helmets may protect, but what is not as easily
recognizable is the damage these weapons are doing to service members´ brains.
Sometimes it is an obvious injury; other times it is mild to moderate.
Therefore, we are considering modifying our study protocol to include
moderate/mild TBI cases. As a company, we believe it is our duty to help these
men and women who otherwise have little to no solution when afflicted with a
brain injury. We are pleased that the Israeli Medical Corps will allow soldiers
to participate," said Chris Stern, Chairman and Chief Executive Officer of
Oxygen Biotherapeutics.

Currently, Oxygen Biotherapeutics has a Phase II-b clinical study underway to
determine the safety and efficacy of using Oxycyte intravenously to treat severe
TBI patients. These studies are being conducted at clinical sites in
Switzerland and Israel with plans to expand into India. The company expects to
allocate a substantial portion of its financial and business resources over the
next few years to testing Oxycyte and advancing this product to regulatory
approval for use in one or more medical applications.

end of ad-hoc-announcement
================================================================================
Oxycyte oxygen carrier is a perfluorocarbon emulsified with water and a
surfactant, which is provided to the patient intravenously. The physical
properties of Oxycyte enable it to gather oxygen from the lungs and transport
the oxygen through the body releasing it along the way. Increased oxygenation
is vital for the recovery of TBI patients. TBI is a non-degenerative,
non-congenital insult to the brain from an external mechanical force, possibly
leading to permanent or temporary impairment of cognitive, physical, and
psychosocial functions, with an associated diminished or altered state of
consciousness.

About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that
efficiently deliver oxygen to tissues in the body. The Company has developed a
proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and liquid
ventilation product called Oxycyte® that is being formulated for both
intravenous and topical delivery for conditions including but not limited to
traumatic brain injury, decompression sickness and topical wounds. This same
PFC is included in the Company’s full line of personal skin care products. More
information is available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by the company
that involve risks and uncertainties and reflect the company's judgment as of
the date of this release. These statements include the expansion of development
of the Oxycyte and DERMACYTE product lines and the timing of the introduction of
those new products. The forward-looking statements are subject to a number of
risks and uncertainties including matters beyond the company's control that
could lead to delays in new product introductions and customer acceptance of
these new products, and other risks and uncertainties as described in our
filings with the Securities and Exchange Commission, including in the current
reports on Form 10-Q and Form-10K. The company disclaims any intent or
obligation to update these forward-looking statements beyond the date of this
release. This caution is made under the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995.

Further inquiry note:
Ellen Corliss

Vice President, Corporate Communications        
& Investor Relations                    
Oxygen Biotherapeutics, Inc     
2530 Meridian Pkwy, 3rd floor   
Durham, NC 27713                
Direct Telephone: +1 919 806 4405                       
Direct Fax: +1 919 806 4417     
Email: [email protected]
end of announcement                               euro adhoc

--------------------------------------------------------------------------------

issuer:   Oxygen Biotherapeutics Inc.
          2530 Meridian Pkwy 
          US-27713 Durham, NC
phone:    +1(919)7607606
FAX:      +1(419)7108764
mail:     [email protected]
WWW:      www.oxybiomed.com
sector:   Biotechnology
ISIN:     US69207P2092
indexes:  SSIRT

stockmarkets: Nasdaq: New York, Main Standard: SIX Swiss Exchange
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print